2024-515135-29-00招募中2 期
Treatment of patients with advanced breast cancer harboring TP53 mutations with dose-dense cyclophosphamide - The p53 breast cancer trial
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 63
- 试验地点
- 4
- 主要终点
- Objective response rate
研究概览
简要总结
The primary objectives of this trial is to prospectively evaluate the objective response rate (ORR)* of dose dense cyclophosphamide in patients with TP53 mutated breast cancer or TP53 wt breast cancer.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Primary (T2 tumors or Locally advanced breast cancers; LABC) in need of pre-surgical chemotherapy or metastatic breast cancer in need of chemotherapy.
- •Before patient registration, written informed consent must be given according to national and local regulations.
- •Blood test requirements: ▪ Neutrophils > 1.0 x 109/L ▪ Platelets > 75 x 109/L ▪ Bilirubin < 20 μmol/L. ▪ Serum creatinine < 1.5 x ULN
- •Resistance to endocrine therapy: Either i) estrogen and progesterone negative tumor, or ii) harboring an estrogen and / or progesterone positive tumor where regular endocrine therapies have failed or where the treating physician finds endocrine therapy not indicated
- •Prior cancer therapy: Metastatic disease: First line treatment: No prior chemotherapy*. Prior endocrine therapy +/- CDK4/6 inhibitor or mTOR inhibitors is allowed if hormone receptor positive, HER2 negative disease. * Only for patients with TP53 mutated disease. Previous adjuvant chemotherapy, including alkylating agents (cyclophosphamide a.o.) DocuSign Envelope ID: 00482556-BD7E-48A0-B3D5-54A7D3046AD9 Study protocol: The p53 breast cancer trial, version 1.9 24 and/or platinum, is allowed if completed >12 months prior to inclusion in the trial. Late-stage disease (approved protocol): i) Prior exposure to and resistance to a taxane regimen**. ii) Prior exposure to and resistance to an anthracycline regimen*** - iii) Previous adjuvant chemotherapy, including alkylating agents (cyclophosphamide a.o.) and/or platinum, is allowed if completed >12 months prior to inclusion in the trial. Primary breast cancer (T2 tumors or LABC): i) Prior exposure to and lack of response to a taxane regimen**. ii) Prior exposure to and lack of response to an anthracycline regimen*** *** Mandatory only for patients with TP53 wt tumors. ** For HER2 positive breast cancer, previous taxane + anti-HER2 treatment is required. In metastatic breast cancer resistance to taxanes/anthracyclines is defined as progressive disease (PD). In primary breast tumors lack of response is defined as stable disease (SD) after 4 courses of chemotherapy or PD, or SD/PD after initial response, or further taxane/anthracyclines is not possible due to toxicity. Breast cancer relapsing within 12 months subsequent to adjuvant taxanes or anthracyclines is considered resistant and re-exposure is not required prior to inclusion in the trial. This relates also to patients who could not receive proper taxane or anthracycline therapy due to side effects or other medical reasons.
- •The primary tumor or at least one metastatic lesion must be available for biopsy collection at protocol inclusion. Notably; for patients with primary metastatic breast cancer, TP53 status should be determined in a metastatic deposit; tissue from the primary tumor may not substitute (this relates both to patients with synchronous and metachronous metastatic disease).
- •Patients must have clinically and/or radiographically documented measurable breast cancer according to RECIST.
- •WHO performance status 0-1
- •Known tumor ER, PGR and HER2 status in the current situation, i.e. archival and historic breast cancer tissue can not be used for patients with relapse of the disease. However, patients can be included regardless of hormone receptor and HER2 status; in case such information lacks at inclusion, it may be analysed on the biopsy retrospectively.
- •Age >18 years
- •Radiology studies for tumor measurements and ecco cor for cardiac function must be performed within 28 days of commencing treatment per protocol (MRI breast for primary breast cancer and CT thorax/abdomen/pelvis and/or MRI + bone scintigraphy/bone scan for metastatic disease).
排除标准
- •Co-morbidity that, based on the assessment of the treating physician, may preclude the use of cyclophosphamide at actual doses.
- •Patients with HER2 positive, metastatic breast cancer in the first line setting (Arm C).
- •Amendment 2021: Previous platinum or cyclophosphamide chemotherapy (incl. EC90) if completed less than 12 months prior to inclusion in the trial.
- •Psychological, familial, sociological or geographical condition(s) potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- •Pregnant or lactating patients
- •Clinical evidence of serious coagulopathy. Prior arterial/venous thrombosis or embolism does not exclude patients from inclusion, unless patient is considered unfit by study oncologist.
- •Active cystitis (to be treated upfront)
- •Active bacterial infections
- •Urinary obstruction
- •Known hypersensitivity towards cyclophosphamide or pegfilgrastim, their metabolites and other ingredients in the drug administration formulation.
- •Patient not able to give an informed consent or comply with study regulations as deemed by study investigator.
结局指标
主要结局
Objective response rate
Objective response rate
次要结局
- pCR, Clinical benefit rate, Recurrence-free survival, safety and tolerability
研究者
Hanne Elisabet Dillekås
Scientific
Helse Bergen HF
研究点 (4)
Loading locations...
相似试验
招募中
2 期
A Clinical Trial for Patients with Advanced Cancers2024-515020-36-00Corbus Pharmaceuticals Inc.108
招募中
2 期
Herombopag Treated T-DM1 Induced Platelet ReductionThrombocytopeniaNCT07257809Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University56
尚未招募
不适用
A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.Breast CancerNCT07290166Fudan University42
进行中（未招募）
2 期
一项芦康沙妥珠单抗治疗局部晚期或转移性胸腺癌的临床研究CTR2025497030
招募中
1 期
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor PatientsNCT07260305Kangabio AUSTRALIA LTD PTY57